Trial Profile
A Phase II study of TNX-102 for the treatment of agitation in Alzheimer's disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2020
Price :
$35
*
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Agitation
- Focus Registrational; Therapeutic Use
- Sponsors Tonix Pharmaceuticals Holding Corp
- 24 Mar 2020 According to a Tonix Pharmaceuticals media release, this study could potentially serve as a pivotal efficacy study to support a New Drug Application (NDA) approval.
- 13 Aug 2018 According to a Tonix Pharmaceuticals Holding Corp media release, the company has submitted a study protocol to FDA in July 2018 and is waiting for the review and acceptance. This would be the potential pivotal study.
- 01 May 2018 According to a Tonix Pharmaceuticals media release,t he U.S. Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) application.